Targeted drug duo takes on rare BRAF cancers in new trial
NCT ID NCT04439292
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study tests two targeted drugs, dabrafenib and trametinib, in 35 adults with advanced cancers (like lymphoma or solid tumors) that have a BRAF V600 mutation. The drugs block proteins that help cancer grow. The goal is to see if the combination can shrink tumors or stop them from getting worse. This is not a cure, as ongoing treatment is needed to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.